Nirmidas Biotech has begun the commercialization of this exciting new technology!
Nirmidas Biotech Inc. has licensed a patent from Stanford University on biocompatible NIR-II dye that can be excited in the 600-900 nm range and fluoresces in the 900-1300 nm range.
This NIR-II dye product (IR-E1100) has high quantum yield (~ 4 times higher than the Stanford dye and carbon nanotube based dyes), high biocompatibility, and can be renal excreted. This dye can be used for fluorescence imaging with low autofluorescence/low background ex vivo with cells and tissues.
It is the first commercial NIR-II dye for deep-tissue in vivo fluorescence imaging with various animal models related to cancer, brain, and cardiovascular diseases and vascular imaging in general. In vivo NIR-II fluorescence imaging can reach millimeters to centimeters tissue depth with spatial resolution in the sub-5 micron to sub-100 micron range. High temporal resolution can also be achieved to produce real-time imaging videos with imaging rate more than 30 frames per second.
This dye holds a high potential for clinical translation for human use due to its large Stokes' shift (excitation 785nm or 808nm, emission 900nm-1300nm), high quantum yield, low toxicity and rapid elimination from body.
Product available: http://www.nirmidas.com/products/niriidye/
Stanford University spinout Nirmidas Biotech has raised $2 million in seed funding to commercialize its fluorescence technology that enhances 100-fold a researcher’s ability to detect disease biomarkers, said the company’s R&D director Joshua Robinson. It’s meant to pick up the subtle traces found in blood from early-stage cancer or hard-to-read autoimmune disorders – conditions that typically use fluorescent dye tests."
"Nirmidas Biotech Inc., a spin-out from Stanford University with technology that amplifies fluorescence in laboratory samples in a bid to better identify disease, has raised $2 million in seed funding to begin commercialization, the company said. The funding was led by an undisclosed Washington-based firm, joined by an undisclosed angel investor and the Stanford-StartX Fund, the company said." Nirmidas Biotech Raises $2M For Gold Nanomaterial Developed at Stanford
"With pGOLD technology, afflictions such as cancer, auto-immune disorders, cardiovascular disease, and diabetes can be detected at earlier stages and with better accuracy by creating non-invasive, point-of-care testing. Early detection could significantly change the nature and cost of patient care."
A plasmonic chip to diagnose type-1 diabetes? This is exactly what researchers at Stanford University have invented. The chip, capable of detecting biomarkers such as insulin-specific autoantibodies, might be used in hospitals and doctors surgeries as a quick and simple way to detect early-stage T1D.